Cross-agency comparison: 🇪🇺 EMA leads with 50 documents in 90 days

FDA vs EMA vs MHRA vs Health Canada — who's most active?

This cross-agency pattern suggests the EMA has been materially more active than the other major agencies over the past 90 days, with Health Canada, FDA, and MHRA forming a second tier of comparatively lower but still meaningful output. Sponsors should consider this a signal that Europe may be the most dynamic environment for near-term policy interpretation and dossier expectations, while North America and the UK may be somewhat less noisy but still require close monitoring for division-specific or procedural shifts. For global filing strategy, this could suggest prioritizing regulatory intelligence and authoring resources toward the EMA-linked workstream first, then scaling submissions and maintenance planning to accommodate staggered updates across the other markets rather than assuming synchronized requirements.